Document is current
Any future updates will be listed below
-
Authors
Li, Dongmei
Xie, Zidian
Shaikh, Sadiya Bi
Rahman, Irfan
-
Funding
Funding for this research was provided by:
National Institute of Environmental Health Sciences (R21ES032159, R21ES032159, R21ES032159)
National Cancer Institute (U54CA228110, U54CA228110, U54CA228110, U54CA228110)
US Food and Drug Administration (U54CA228110, U54CA228110, U54CA228110, U54CA228110)
National Center for Advancing Translational Sciences (UL1 TR002001)
National Institute on Aging (U54AG075931, U54AG075931, U54AG075931, U54AG075931)
- License Information
-
More Information
Article History
Received: 2 July 2024
Accepted: 2 January 2025
First Online: 21 January 2025
Declarations
:
: The PATH Study design and protocol was approved by the Westat Institutional Review Board to protect the rights, welfare, and well-being of all humans involved in this study. All participants provided verbal informed consent before participating in the PATH Study95. Using validated PATH Study standard operating procedures, blood biospecimens were collected from consenting PATH Study participants under a protocol reviewed and approved by the Westat Institutional Review Board. Our applications to the collected plasma biospecimens have been approved by the PATH Study Biospecimen Access Program. The study has been reviewed by the University of Rochester Research Subjects Review Board and was determined as not research involving human subjects. All biospecimens obtained from the PATH biospecimen program were deidentified, and the linkage ID connecting demographic information with the PATH biospecimens were disclosed only after the completion of sequencing experiments on all biospecimens.
: Not applicable.
: The authors declare no competing interests.
